Comparison of budesonide Turbuhaler with budesonide aqua in the treatment of seasonal allergic rhinitis . Rhinocort Study Group . 
<br>
<br> OBJECTIVE To compare the effect of budesonide Turbuhaler 400 microg / day with budesonide aqua 256 microg / day in the treatment of seasonal allergic rhinitis ( SAR ) . Secondarily to ascertain <font color="red">patients_1</font> <font color="red">'_1</font> <font color="red">preferences_1</font> <font color="red">for_1</font> <font color="red">the_1</font> <font color="red">two_1</font> <font color="red">nasal_1</font> <font color="red">devices_1</font> and to assess <font color="red">quality_1</font> <font color="red">of_1</font> <font color="red">life_1</font> <font color="red">._1</font> 
<br> DESIGN Randomized , multicentre , double - blind , double- dummy , parallel groups study . 
<br> SETTING Private practices and hospital clinics in Ontario , Quebec and Manitoba . 
<br> POPULATION Two hundred and eighty - four out - patients with SAR , who were symptomatic during the ragweed season , volunteered for enrolment ( 243 randomized ) . 
<br> RESULTS <font color="red">Mean_1</font> <font color="red">daily_1</font> <font color="red">nasal_1</font> <font color="red">symptom_1</font> <font color="red">scores_1</font> were significantly reduced with treatment . There were no statistically significant changes from baseline for <font color="red">eye_1</font> <font color="red">symptoms_1</font> <font color="red">._1</font> Most patients ( more than 80% ) achieved <font color="red">substantial_1</font> <font color="red">control_1</font> <font color="red">of_1</font> <font color="red">their_1</font> <font color="red">symptoms_1</font> with budesonide . The most common <font color="red">nasal_1</font> <font color="red">and_1</font> <font color="red">non_1</font> <font color="red">-_1</font> <font color="red">nasal_1</font> <font color="red">adverse_1</font> <font color="red">events_1</font> for both groups were <font color="red">epistaxis_1</font> and <font color="red">headache_1</font> <font color="red">._1</font> Turbuhaler was <font color="red">easier_1</font> <font color="red">to_1</font> <font color="red">use_1</font> <font color="red">and_1</font> <font color="red">more_1</font> <font color="red">convenient_1</font> <font color="red">to_1</font> <font color="red">carry_1</font> <font color="red">,_1</font> had less of an <font color="red">unpleasant_1</font> <font color="red">taste_1</font> <font color="red">,_1</font> and caused less <font color="red">nasal_1</font> <font color="red">irritation_1</font> than the aqua spray . More than twice as many patients preferred Turbuhaler to the aqua spray ( 69% versus 31% ) . Improvement in <font color="red">quality_1</font> <font color="red">of_1</font> <font color="red">life_1</font> from baseline to clinic visits was statistically significant in both groups . 
<br> CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of budesonide Turbuhaler are equally <font color="red">safe_1</font> and <font color="red">efficacious_1</font> in the treatment of SAR . <font color="red">Patients_1</font> <font color="red">preferred_1</font> the budesonide powder formulation delivered via Turbuhaler two to one over the aqua formulation .